Huperzine A

Huperzine A may present with mild cholinergic side effects such as nausea, vomiting, and diarrhea. ==Pharmacology==

Huperzine A is a potent, highly specific, reversible acetylcholinesterase inhibitor, with IC50 binding affinity of ~82 nM. It is also a weak NMDA receptor antagonist, with IC50 of ~65,000–82,000 nM Acetylcholinesterase is an enzyme that catalyzes the breakdown of choline-based neurotransmitters, particularly acetylcholine (ACh), which plays a critical role in memory, learning, and behavior. The structure of the complex of huperzine A with acetylcholinesterase has been determined by X-ray crystallography (PDB code: 1VOT; see the 3D structure). ==Drug interactions==

Huperzine A may have additive effects if taken with drugs causing bradycardia, such as beta blockers, which may decrease heart rate. Theoretically, there may be possible additive cholinergic effects if huperzine A is taken with other acetylcholinesterase inhibitors or cholinergic agents. ==Safety==

Huperzine A, in spite of the possible cholinergic side effects, seems to have a wide margin of safety. Toxicology studies show huperzine A to be non-toxic even when administered at 50–100 times the human therapeutic dose. The extract is active for 6 hours at a dose of 2 μg/kg with no remarkable side effects. ==Synthesis==

Two scalable and efficient total syntheses of huperzine A have been reported. == History ==

In 1989, a research study found that the chemical structure of the alkaloid selagine reported in 1960 from a study of Lycopodium slago L. (analyzed using 60-MHz NMR) was identical to that of Huperzine A. == Research ==

Effects Huperzine A has been investigated as a possible treatment for diseases characterized by neurodegeneration such as Alzheimer's disease, and there is some evidence from small-scale studies that it can benefit cognitive functioning, global clinical status, and ability to engage in activities of daily living (ADLs) among individuals with the disease. In a 2016 systematic review of systematic reviews, huperzine A was associated with a standardized mean difference of 1.48 (95% CI, 0.95–2.02) compared to placebo on measures of ADL among people with dementia, but the evidence was very low-quality and uncertain. In a 2022 umbrella review, huperzine A was associated with broad benefits to dementia patients' cognitive functioning, but the degree of heterogeneity in measurements and outcomes of the reviewed studies indicated publication bias toward huperzine A benefit. Use in organophosphate poisoning Huperzine A might be useful in the treatment of organophosphate nerve agent poisoning by preventing damage to the central nervous system caused by such agents. Use as oneirogen Huperzine A may be used as a (very weak) Oneriogen. == References ==